DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A

L. M. Henricks; C. A. T. C. Lunenburg; F. M. de Man; D. Meulendijks; G. W. J. Frederix; E. Kienhuis; G. J. M. Creemers; A. Baars; V. O. Dezentjé; H. Rosing; J. H. Beijnen; E. van Werkhoven; A. B. P. van Kuilenburg; R. H. N. van Schaik; R. H. J. Mathijssen; J. J. Swen; H. Gelderblom; A. Cats; H. J. Guchelaar; J. H. M. Schellens

doi:10.1093/annonc/mdy281

DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A

L. M. Henricks
, C. A. T. C. Lunenburg
, F. M. de Man
, D. Meulendijks
, G. W. J. Frederix
, E. Kienhuis
, G. J. M. Creemers
, A. Baars
, V. O. Dezentjé
, H. Rosing
, J. H. Beijnen
, E. van Werkhoven
, A. B. P. van Kuilenburg
, R. H. N. van Schaik
, R. H. J. Mathijssen
, J. J. Swen
, H. Gelderblom
, A. Cats
, H. J. Guchelaar
, J. H. M. Schellens

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	viii150
Journal	Annals of oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy281
Publication status	Published - 2018

Access to Document

10.1093/annonc/mdy281

Cite this

Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G. J. M., Baars, A., Dezentjé, V. O., Rosing, H., Beijnen, J. H., van Werkhoven, E., van Kuilenburg, A. B. P., van Schaik, R. H. N., Mathijssen, R. H. J., Swen, J. J., Gelderblom, H., Cats, A., Guchelaar, H. J., & Schellens, J. H. M. (2018). DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A. Annals of oncology, 29, viii150. https://doi.org/10.1093/annonc/mdy281

@article{c0c6a45307334875b44630bcf2e3f4e5,

title = "DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A",

author = "Henricks, \{L. M.\} and Lunenburg, \{C. A. T. C.\} and \{de Man\}, \{F. M.\} and D. Meulendijks and Frederix, \{G. W. J.\} and E. Kienhuis and Creemers, \{G. J. M.\} and A. Baars and Dezentj{\'e}, \{V. O.\} and H. Rosing and Beijnen, \{J. H.\} and \{van Werkhoven\}, E. and \{van Kuilenburg\}, \{A. B. P.\} and \{van Schaik\}, \{R. H. N.\} and Mathijssen, \{R. H. J.\} and Swen, \{J. J.\} and H. Gelderblom and A. Cats and Guchelaar, \{H. J.\} and Schellens, \{J. H. M.\}",

year = "2018",

doi = "10.1093/annonc/mdy281",

language = "English",

volume = "29",

pages = "viii150",

journal = "Annals of oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Henricks, LM, Lunenburg, CATC, de Man, FM, Meulendijks, D, Frederix, GWJ, Kienhuis, E, Creemers, GJM, Baars, A, Dezentjé, VO, Rosing, H, Beijnen, JH, van Werkhoven, E, van Kuilenburg, ABP, van Schaik, RHN, Mathijssen, RHJ, Swen, JJ, Gelderblom, H, Cats, A, Guchelaar, HJ & Schellens, JHM 2018, 'DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A', Annals of oncology, vol. 29, pp. viii150. https://doi.org/10.1093/annonc/mdy281

TY - JOUR

T1 - DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A

AU - Henricks, L. M.

AU - Lunenburg, C. A. T. C.

AU - de Man, F. M.

AU - Meulendijks, D.

AU - Frederix, G. W. J.

AU - Kienhuis, E.

AU - Creemers, G. J. M.

AU - Baars, A.

AU - Dezentjé, V. O.

AU - Rosing, H.

AU - Beijnen, J. H.

AU - van Werkhoven, E.

AU - van Kuilenburg, A. B. P.

AU - van Schaik, R. H. N.

AU - Mathijssen, R. H. J.

AU - Swen, J. J.

AU - Gelderblom, H.

AU - Cats, A.

AU - Guchelaar, H. J.

AU - Schellens, J. H. M.

PY - 2018

Y1 - 2018

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85081532685&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/32136250

U2 - 10.1093/annonc/mdy281

DO - 10.1093/annonc/mdy281

M3 - Meeting Abstract

C2 - 32136250

SN - 0923-7534

VL - 29

SP - viii150

JO - Annals of oncology

JF - Annals of oncology

ER -

DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A

Access to Document

Other files and links

Cite this